Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development
03 janv. 2023 06h58 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through...
Landkind reaches significant regulatory milestone, achieving GRAS status for LK-01™ Pure Salidroside
19 déc. 2022 08h00 HE
|
DoubleRainbow Biosciences
LEXINGTON, MASS., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Landkind, a subsidiary of DoubleRainbow Biosciences leveraging advances in synthetic biology to deliver precision-engineered supplements to...
Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
15 déc. 2022 06h59 HE
|
Synlogic, Inc.
Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar...
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
30 nov. 2022 16h15 HE
|
Synlogic, Inc.
Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract SYNB1353 has been granted Orphan Drug Designation (ODD) from the FDA...
Double Rainbow Announces World’s First Commercial-Scale Biosynthetic Gastrodin, a Natural Analgesic with a Range of Therapeutic Applications
28 nov. 2022 09h41 HE
|
DoubleRainbow Biosciences
Lexington, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (“Double Rainbow”), a sustainable biotech company harnessing bioengineering to improve the quality of human health,...
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
10 nov. 2022 06h59 HE
|
Synlogic, Inc.
Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023 Clinical readouts for SYNB1353 for...
Synthetic Biology Global Market Report 2022: Extensive Applications Of Synthetic Biology Drive Sector Growth
08 nov. 2022 08h43 HE
|
Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Synthetic Biology Market Size, Share & Trends Analysis Report by Product (Enzymes, Cloning Technologies Kits), by Technology (PCR, NGS), by...
DoubleRainbow Biosciences Announces Strategic AI Collaboration with Galixir
07 nov. 2022 08h10 HE
|
DoubleRainbow Biosciences
LEXINGTON, MASS., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Double Rainbow, a sustainable health care company harnessing the power of natural evolution through bioengineering to improve the quality of human...
Global Synthetic Biology Market Report 2022: High Potential Opportunities in Agriculture, Manufacturing & Medicine
07 nov. 2022 04h28 HE
|
Research and Markets
Dublin, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Synthetic Biology Market, By Products, By Application, By Tool, By Technology & By Region- Forecast and Analysis 2022-28" report has been...
Synthetic Biology Market Size Worth $32.73 Bn by 2028 | Vantage Market Research
26 oct. 2022 06h04 HE
|
Vantage Market Research
WASHINGTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- According to a report by Vantage Market Research, the Global Synthetic Biology Market was worth USD 10.11 Billion in 2021 and is expected to be worth...